Patients with renal cell carcinoma treated with neoadjuvant bevacizumab demonstrated reduced CD31+ MVD and a reduced number of total CD68+, but not CD163+ TAMs in comparison with untreated patients [230]. This evidence concerns the gene CD163 and hereditary clear cell renal cell carcinoma.